Download “Здоровье -2011-7 РП (5-й конкурс)” (презентация 16.07.2010)

Health Work Programme 2011FP7 (5th year calls)
Рабочая программа «Здоровье-20117РП » (5-й конкурс)
Директорат «Здоровье»
Генеральный директорат по
науке
Европейская комиссия
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
June 2009
1
HEALTH-NCP-NET – это
сеть,
объединяющая
Национальные
контактные
точки
(НКТ)
по
приоритетному направлению «Здоровье»
в Европе
и контактные точки за ее
пределами.
Сайт Еврокомиссии по приоритетному
направлению «Здоровье»:
http://cordis.europa.eu/fp7/health/home_en.html
Национальный информационный офис 7 РП ЕС в
Беларуси: http://fp7-nip.org.by/
Руководитель офиса:
Мееровская Ольга Анатольевна
тел. +375 17 2867630
e-mail:[email protected]
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
2
ГНУ «Институт биофизики и клеточной
инженерии НАН Беларуси»
г. Минск, ул. Академическая, 27
e-mail: [email protected]
http://ibp.org.by/ru/?page_id=229
тел. + 375 17 284 15 68
+ 375 17 284 23 57
факс: + 375 17 284 23 59
НАЦИОНАЛЬНАЯ КОНТАКТНАЯ ТОЧКА 7РП ЕС
ПО ПРИОРИТЕТНОМУ НАПРАВЛЕНИЮ «ЗДОРОВЬЕ»
Приказом Государственного комитета по науке и технологиям от 16 марта 2007 г. № 28 «О
развитии научно-технического сотрудничества с Европейским Союзом» Институт биофизики и
клеточной инженерии назначен Национальной контактной точкой (НКТ) 7РП ЕС по
приоритетному направлению «Здоровье».
Основные направления деятельности:
Распространение информации о возможностях участия белорусских ученых в проектах 7 Рамочной
Программы.
Консультирование действующих и потенциальных участников из Беларуси по вопросам подготовки
заявок и реализации проектов.
Поиск партнеров в странах ЕС для белорусских организаций, желающих присоединиться к
формирующимся консорциумам, и наоборот – поиск партнеров в Беларуси по запросам организаций из
ЕС.
Реклама научно-технического потенциала Беларуси в странах ЕС для продвижения участия
отечественных ученых в проектах 7 РП.
Проведение информационных дней и семинаров.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
3
Типы программ
7РП Европейского союза
• Cooperation (сотрудничество) –
• Ideas (идеи) –
• Реople (люди) • Capacities (cпособности) –
• Joint Research Projects (совместные
исслед. проекты) –
• Euroatom (евроатом)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
4
•
•
•
•
•
•
•
•
Приоритеты научной и научно-технической деятельности
Европейского союза
1.Energy (Энергетика )
2.Environment (including Climate Change) (Окружающая среда,
включая изменения климата)
3.Food, Agriculture and Fishery, Biotechnology (Питание, сельское и
рыбное хозяйство,биотехнологии)
4.Нealth(Здоровье)
5. Information and Communication Technologies (Информационные
и коммуникационные технологии)
6. Nanosciences, Nanotechnologies, Materials and new Production
Technologies (Нанонауки, нанотехнологии, материалы и новые
производственные технологии )
7. Socio-economic sciences and Humanities (Социальноэкономические и гуманитарные науки)
8. Transport (including Aeronautics) (Транспорт, включая
аэронавтику)
• 9. Security (Безопасность)
По приоритетам Еврокомиссия объявляет ежегодные
конкурсы
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
5
Схемы финансирования
• Collaborative projects (совместные проекты);
• Networks of excellence (сети превосходства)
• Coordination and support actions (работы по
координации и поддержке)
• Individual projects (индивидуальные
проекты)
• Support for training and career development
of researches (поддержка совершенствования
и карьерного роста исследователей)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
6
Совместные
проекты
Выполняются консорциумами из представителей различных стран, проекты
преследуют задачи: получение новых
знаний, создание новых технологий и
продукции, выполняются в рамках
приоритетов
по
различным
темам,
предложено 3 типа совместных проектов
(малые, средние и крупные), проекты
могут быть ориентированы на специальные группы, например, SME.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
7
• Сети превосходства
• Поддерживают совместные программы ряда
организаций (Joint Programme Activities),
объединяющих свою деятельность в определенной области исследований в ходе
длительной кооперации
• Работы по координации и
поддержке
• Поддерживают деятельность по координации и
поддержке научных исследований (создание
сетей, обмены учеными и информацией,
транснациональный доступ к инфраструктурам
и исследованиям, проведение конференций)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
8
• Индивидуальные проекты
Осуществляются национальными или
международными группами ученых по
новым актуальным научным направлениям во взаимодействии с Европейским
научно-исследовательским советом
• Поддержка совершенствования
и карьерного роста ученых
Осуществляется через систему грантов
им. Марии Кюри
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
9
Сети 7РП
В рамках схемы Coordination and Support
Action Еврокомиссия создала ряд сетей:
• IncoNet EECA http://www.inco-eeca.net
• IncoNet CA/SC - S&T International Cooperation Network
for Central Asian and South Caucasus Countries
http://icbss.org/index.php?option=com_content&task=view&id=2
73
• incrEAST - Information Exchange in Science and
Technology between the European Research Area and
Eastern European / Central Asian Countries
http://www.increast.eu/
• HEALTH-NCP-NET http://www.healthncpnet.eu/jahia/Jahia/
• INCONTACT network of the INCO-NCPs http://www.ncpincontact.eu/nkswiki/index.php?title=Main_Page
• HITT-CIS - Health In Times Transition: Trends in Population
Health and Health Policies in CIS countries http://www.hittcis.net/
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
10
ERA-NETs:
• ERA.NET RUS Linking Russia to the ERA: Coordination
of MS´/AC´ S&T programmes towards and with Russia
http://www.era.net-rus.eu/,
http://ec.europa.eu/research/iscp/pdf/russia_eranet.pdf
• BS-ERA.NET Networking on science and technology in
the Black Sea region http://www.bs-
era.net/main/index.php?we=9bfdbe988abcff430168e60524a69c11&wchk=c
1960ad06e70dbaee80ab8641db51532,
http://ec.europa.eu/research/iscp/pdf/black_sea.pdf
BILATs
• BILAT-RUS Enhancing the bilateral S&T Partnership
with the Russian Federation http://www.bilat-rus.eu/,
http://ec.europa.eu/research/iscp/pdf/russia_bilat.pdf
• BILAT-UKR Enhancing the bilateral S&T Partnership
with Ukraine, http://www.bilat-ukr.eu/,
http://ec.europa.eu/research/iscp/pdf/ukraine.pdf
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
11
Participation and Success
Rate in FP7 Health Research
• The countries of Eastern Europe and Central Asia
include: Armenia, Azerbaijan, Belarus, Georgia,
Kazakhstan, Kyrgyzstan, Moldova, the Russian
Federation, Turkmenistan, Tajikistan, Ukraine and
Uzbekistan. (EECAlink focuses on those underlined)
• FP6:
Armenia (3 - 250k€), Belarus (1 - 22k€),
Ukraine (8 - 650k€), Russia (38 - €5.8Mio)
• FP7:
Armenia (8/2/25%), Belarus (12/2/17%) ,
Georgia (10/4/40%), Kazakhstan (9/2/22%), Moldova
(7/3/43%), Russia (113/25/22%),
•
Ukraine (28/5/18%), Uzbekistan (2/1/50%)
CPM Status March 2010
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
12
5-ый конкурс
«Здоровье»
•
•
•
Бюджет: €650m
Дата объявления: 30 July 2010
Последняя дата внесения проектов :
-
-
FP7-HEALTH-2011-single-stage, deadline: 10
Nov. 2010 (tbc)
FP7-HEALTH-2011-two-stage, deadline: 13 Oct.
2010 (tbc)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
13
Некоторые данные
по 7РП «Здоровье»
FP7 HEALTH
Proposals received
все страны- 21’829 , третьи страны
N° of participations
Grant Agreements
(N° of participations
EU funding
2315
405
4241
1464
591
123
327
€1’606 Mio
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
14
Приоритеты 5-ого
конкурса
• Области главных приоритетов:
– the brain: neurodegenerative + lifestylerelated aspects
– diabetes/obesity & lifestyle-induced
conditions
– antimicrobial drug resistance
– emerging epidemics
– health inequalities, …
• Исследовательские инициативы высокой
значимости:
– Epigenomics
– Better immunisation
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
15
Исследовательские
инициативы высокой значимости
• Major strategic investments to foster European
competitive position in target areas with important
economical/societal return
• Programmatic approach (structuring the ERA):
several research components integrated in each project,
allowing synergies.
• High-impact outcomes expected from coherent &
ambitious strategies
• Collaborative Project, but larger in size (€30 Mio)
• Participation of SMEs (min. 15% of EU contribution to
each project)
• Governance and management will be critical.
• Adapted evaluation: single-stage, with hearings
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
16
Тематика
клинических испытаний
Руководящие принципы:
• Двустадийная схема внесения
• Вклад EC : max. €6m/project in most cases
• Читсло партнеров: в каждом случае свое (with minimum 3)
• Продолжительность проектов: по усмотрению заявителей
• Поощряется участие больных
• Предусмотрены этические моменты (EU and national)
• Возможно участие субподрядчиков
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
17
Тематика
клинических испытаний
Цель:
• Translating research into clinical practice
• Focus on investigator-driven CTs – relevant to
public health
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
18
SME участие
Одна из задач: облегчить и
увеличить участие SME
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
19
Принципы международного сотрудничества
• Болезни не имеют границ, поражают население богатых и бедных
стран
• Здоровье является политическим
приоритетом для большинства стран
(богатых и бедных)
• Болезни богатых (рак, диабет, сердечно-сосудистые заболевания и др.
) поражают население развивающихся стран и, наоборот (малярия,
туберкулез,…).
• Лечение
всегда
универсально
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
20
• Все темы открыты для участников
из третьих стран
• Некоторые темы имеют целевое
значение
• Ряд тем получил название Specific
International Cooperation Actions
(так называемые SICAs)
– Address specific issues that partner
countries face or have a global character,
on the basis of mutual interest and
benefit
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
21
Ключевые
факторы успеха
– Предложения должны быть адресованы
тематике, рабочей программе,
конкретными не расплывчатыми; (not
wishful thinking)
– Консорциум партнеров должен быть
превосходным и соответствовать
задачам (select the right partners)
– Предложения должны соответствовать
всем требуемым критериям
– Должны быть убедительными для
рецензента (don’t rely on reputation)
– Соответстовать основным правилам
(deadlines, N° of participants, ceilings, length,
ethics
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
22
• 3 критерия соответствия;
•
Science & Technology excellence
Пороги
3/5
Implementation & Management
3/5
Potential Impact
Overall
3/5
10/15
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
23
Европейское
исследовательское пространство
(R&D aria)
• 27 EU Member States
• +7 Outermost Regions
• Guadeloupe, French Guiana, Martinique and Réunion (the
four French overseas departments), the Canaries (Spain),
and the Azores and Madeira (Portugal)
• +12 Associated Countries
(the EU neighbourhood countries)
• Albania, Bosnia and Herzegovina, Croatia, Iceland , Israel,
Liechtenstein, FYR of Macedonia, Norway, Republic of
Montenegro, Serbia, Switzerland, Turkey
• +FP7 Third Countries
• Other countries worldwide
- can participate in FP7
• - some can receive funding (ICPC, incl. BRICS) and
others only exceptionally (high-income countries)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
24
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
25
Участие третьих
стран
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
26
• Участие Восточноевропейских стран
(2007-2010)
• Russia: 35
• Ukraine: 6
• Georgia: 5
• Rep.Moldova: 4
• Belarus: 3
• Armenia, Kazakhstan: 2
• Uzbekistan: 1
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
27
Требования и
финансирование
• Для большинства типов проектов (CP-IPs,
small/medium CP-FPs):
• Минимальное число участников: 3 из MS/AS
• Средний объем: большой CP-IPs – €10.7 Mio /17 partners,
средний CP-FP - €3.5 Mio / 10 partners, малый CP-TP –
€3.2 Mio / 8 partners
• Средний показатель участия третьих стран: 30% по
грантам, 8% по участникам
• Specific International Cooperation Actions
• Минимальное число участников: 2+2 (2 from MS/AS + 2
from ICPCs)
• В среднем от третьих стран: 4 partners
• Средний объем: CP-SICA - €3.4 Mio / 9 partners (5
MS/AS + 4 TC)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
28
Возможности
5-ого конкурса c точки
зрения сотрудничества
•
•
•
Programme-Level Cooperation with:
– Russia:
1.1-3 HTP Proteomics
– Brazil:
1.1.4-5 Inflammatory and Autoimmune diseases
– India:
2.2.1-4 Neurodegenerative paediatric diseases
– India:
2.4.1-3 Cancer from Infectious Agents
– Brazil:
3.4-3 Multilateral cooperation in Public Health
Specific International Cooperation Actions:
– 2.1.1-4
Pop. Genetics on Cardio-Metabolic Disorders
– 2.3.3-2
Control of Dengue Fever
– 2.4.3-4
Obesity and/or Diabetes in Specific Populations
– 3.4-1
Reproductive Health and Health Equity
Other topics of particular international nature:
– 2.3.3-1
Zoonotic Viruses
– 2.3.3-3
Major Epidemic Outbreaks
– 2.3.1-2
Evolution/transfer of AMDR
– 3.3-1
Determinants of Health
– 3.4-2
Research Capacity
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
29
Где искать
информацию?
• Calls for Proposals, Work Programme
(Topics)
http://cordis.europa.eu/fp7/health/
• National Contact Points (NCPs) - Information
& support for applicants
http://www.healthncpnet.eu
• FP6/FP7 projects databases
http://www.lifecompetence.eu/;
http://www.healthcompetence.eu/
• Partner search tools
http://www.smesgohealth.org/
• EU health research website
http://ec.europa.eu/research/health/
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
30
• Proposed topics for 2011 WP
•
• Activity 1 - Биотехнология, методы и технологии для медицины
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
31
Биотехнология, методы и технологии
High-throughput research
• 1.1 –
•
• 1.1-1 SME-targeted research for developing tools and
technologies for high-throughput research.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.1-2 Genome-based biomarkers for patient stratification
and pharmacogenomic strategies.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.1-3 High-throughput proteomics for human health and
disease. (Russia)
• Funding scheme: collab. project, max €3m, single-stage, one or
more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
32
Биотехнология, методы и технологии
• 1.2 - Detection, diagnosis and
monitoring
•
• Closed in 2011
– 1.3 - Suitability, safety, efficacy of
therapies
–
– Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
33
Биотехнология, методы и технологии
• 1.4 Innovative therapeutic approaches and
interventions
• 1.4-1 Regenerative medicine clinical trials.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.4-2 Tools, technologies and devices for application in
regenerative medicine.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 1.4-3 Development and production of new, high-affinity
protein scaffolds for therapeutic use.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
34
Биотехнология, методы и технологии
1.4 – Innovative therapeutic
approaches and interventions
– 1.4-4 High impact project immunisation.
– Funding scheme: collab. project, max €30m,
single-stage, max one proposal.
– 1.4-5 New therapeutic approaches in chronic
inflammatory and autoimmune diseases.
(Brazil)
– Funding scheme: collab. project, max €3m,
single-stage, one or more proposals
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
35
• Proposed topics for 2011 WP
• Activity 2 - Сквозные исследования в области здоровья
(translating research for human
health)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
36
Сквозные исследования в области здоровья
• 2.1.1 – large-scale data-gathering:
• 2.1.1-1 High impact initiative on the human epigenome.
• Funding scheme: collab. project, max €30m, single-stage, max
one proposal.
• 2.1.1-2 Proteins and their interactions in health and
disease.
• Funding scheme: collab. project, max €12m, 2-stage, one or more
proposals.
• 2.1.1-3 Large-scale genomics approaches to identify host
determinants of infectious diseases.
• Funding scheme: collab. project, max €12m, single-stage, max
one proposal.
• 2.1.1-4 Population genetic studies on cardio-metabolic
disorders in EU/AC and EECA populations.
• Funding scheme: Specific International Cooperation Action
(SICA),
collab. project, max €6m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
37
Сквозные исследования в области здоровья
• 2.1 – Integrating biological data
and processes
•
2.1.2 – Systems biology
• Closed in 2011.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
38
Сквозные исследования в области здоровья
• 2.2.1 – Research on the Brain and related
diseases, human development and ageing:
– 2.2.1-1 Investigator-driven clinical trials for
childhood-onset neurodegenerative diseases.
– Funding scheme: collab. project, max €6m, 2-stage, one
or more proposals.
– 2.2.1-2 Understanding the role of
neuroinflammation in neurodegenerative diseases.
– Funding scheme: collab. project, max €12m, 2-stage,
one or more proposals.
– 2.2.1-3 Addictive and/or compulsive behaviour in
children & adolescents: translating preclinical
results into therapies
– Funding scheme: collab. project, max €6m, 2-stage, one
or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
39
Сквозные исследования в области здоровья
• 2.2.1 – Research on the Brain and related
diseases, human development and ageing:
– 2.2.1-4 Creating clinical and molecular tools for
experi-mental therapy of paediatric
neurodegenerative disorders causing childhood
dementia in Europe and India.
– Funding scheme: collab. project, max €3m, singlestage, one or more proposals.
– 2.2.1-5: ERA-Net on disease-related neurosciences.
– Funding scheme: CA ERA-NET, ~€2m, single-stage,
max. one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
40
Сквозные исследования в области здоровья
• 2.2.2 – Human development and
ageing:
– 2.2.2-1 Investigator-driven clinical trials
for therapeutic interventions in elderly
populations.
– Funding scheme: collab. project, max €6m, 2stage, one or more proposals.
– 2.2.2-2 Linking human development and
ageing.
– Funding scheme: collab. project, max €3m, 2stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
41
Сквозные исследования в области здоровья
• 2.3-1 Anti-microbial drug resistance
• 2.3.1-1 Investigator-driven clinical trials of off-patent
antibiotics.
• Funding scheme: collab. project, max €6m, 2-stage, one or more
proposals.
• 2.3.1-2 Multi-disciplinary research on the evolution and
transfer of antibiotic resistance.
• Funding scheme: collab. project, max €12m, single-stage, max
one proposal.
• 2.3.1-3 Management of Gram negative multi-drug resistant
infections.
• Funding scheme: collab. project, max €12m, single-stage, max
one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
42
Сквозные исследования в области здоровья
• 2.3-1 Anti-microbial drug resistance
• 2.3.1-4 Development of multi-analyte
diagnostic tests.
• Funding scheme: collab. project, max €3m, 2stage, one or more proposals.
• 2.3.1-5 Development of tools to control
microbial biofilms with relevance to clinical
drug resistance.
• Funding scheme: collab. project, max €3m, 2stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
43
Сквозные исследования в области здоровья
• 2.3.2 – HIV/AIDS, malaria and
tuberculosis
• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
44
Сквозные исследования в области здоровья
• 2.3.3 – Potentially new and re-emerging epidemics
• 2.3.3-1 Identification of factors promoting the emergence
of pathogens with human pandemic potential from
pathogens with a zoonotic background and related
prevention strategies.
• Funding scheme: collab. project, max €12m, two-stage, max one
proposal.
• 2.3.3-2 Comprehensive control of Dengue fever under
changing climatic conditions. (SICA: Latin Am. & Asia)
• Funding scheme: collab. project, max €6m, single-stage, one or
more proposals.
• 2.3.3-3 Development of an evidence-based behavioural and
communication package to respond to major epidemic
outbreaks.
• Funding scheme: collab. project, max €2m, 2-stage, one or more
proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
45
Сквозные исследования в области здоровья
• 2.3.4 – Neglected infectious
diseases
• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
46
Сквозные исследования в области здоровья
• 2.4.1 – Cancer
• 2.4.1-1 Investigator-driven, treatment trials for rare
cancers.
• Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
• 2.4.1-2 Translational research on cancers with poor
prognosis
• Funding scheme: collab. project, max €3m, 2-stage, one or
more proposals.
• 2.4.1-3 Epidemiology and aetiology of infectionrelated cancers (in Europe & India)
• Funding scheme: collab. project, max €3m, 1-stage, one or
more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
47
Сквозные исследования в области здоровья
• 2.4.2 – Cardiovascular disease
– 2.4.2-1 Investigator-driven clinical trials for the
management of cardiovascular diseases.
– Funding scheme: collab. project, max €12m, 2-stage,
one or more proposals.
– 2.4.2-2 Evaluation and validation studies of
clinically useful biomarkers in prevention and
management of cardiovascular disease.
– Funding scheme: collab. project, max €6m, 2-stage, one
or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
48
Сквозные исследования в области здоровья
• 2.4.3 – Diabetes and obesity
• 2.4.3-1 Investigator-driven clinical trials to reduce
diabetes complications.
• Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
• 2.4.3-2 Development of novel treatment strategies
based on knowledge of cellular dysfunction.
• Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
• 2.4.3-3 Molecular and physiological effects of
lifestyle factors on diabetes/obesity.
• Funding scheme: collab. project, max €6m, 2-stage, one or
more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
49
Сквозные исследования в области здоровья
• 2.4.3 – Diabetes and obesity
• 2.4.3-4 Genetic and environmental factors in
obesity and/or diabetes in specific
populations.
• Funding scheme: SICA (Africa, Asia, Latin
America, Mediterranean countries),
max €3m, 2-stage, one or more proposals.
• 2.4.3-5 ERA-NET on diabetes prevention and
treatment.
• Funding scheme: ERA-NET CA, ~€2m, singlestage, max one project.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
50
Сквозные исследования в области здоровья
• 2.4.4 – Rare diseases
• Closed in 2011
• 2.4.5 – Other chronic diseases
• Closed in 2011
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
51
• Proposed topics for 2011 WP
• Activity 3 - Оптимизация оказания лечебной помощи(Optimising the delivery of
health care)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
52
Оптимизация оказания лечебной помощи
• 3.1 – Translating the results of
clinical research outcome into clinical
practice
• Closed in 2011
• 3.2 – Quality, efficiency and
solidarity of healthcare systems
• Closed in 2011.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
53
Оптимизация оказания лечебной помощи
• 3.3 – Health promotion
• 3.3-1 Developing methodologies to reduce inequities in the
determinants of health.
• Funding scheme: collab. project, max €3m, 2-stage, one or more
proposals.
• 3.3-2. Analysis of integrated strategies for sustainable
behaviour change.
• Funding scheme: collab. project, max €3m, 2-stage, one or more
proposals.
• 3.3-3 Developing and implementing methods for the
transfer of research into policy in the fields of health
promotion and disease prevention.
• Funding scheme: collab. project, max €3m, single-stage, max one
proposal.
• 3.3-4 A road-map for mental health research in Europe.
• Funding scheme: CA, max €2m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
54
Оптимизация оказания лечебной помощи
• 3.4 – International public health & health systems
• 3.4-1 Development and assessment of comprehensive and
integrated interventions and programmes to improve
repro-ductive health and health equity.
• Funding scheme: SICA (all ICPC) collab. project, max €3m,
single-stage, one or more proposals.
• 3.4-2 Building sustainable capacity for research for health
and its social determinants in low and middle income
countries.
• Funding scheme: CA, max €2m, single-stage, one or more
proposals.
• 3.4-3 Multilateral cooperation between Europe, Africa and
Latin America on public health and health services
research.
• Funding scheme: CA, max €2m, single-stage, max one proposal.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
55
• Proposed topics for 2011 WP
• Activity 4 - Мероприятия
поддержки и ответ на
требования политики (support
actions & response to policy
need)
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
56
Мероприятия
поддержки
4.1 – Coordination and support actions across the theme
• 4.1-1 Networking of major research institutions to
coordinate communication actions aimed at the media and
the general public.
• Funding scheme: CA, max €2m, single-stage, max one proposal.
• 4.1-2 Targeting publication bias.
• Funding scheme: SA, max €0.5m, single-stage, one or more
proposals.
• 4.1-3 Linking EU and Latin American policy-making
institutions in the field of health research.
• Funding scheme: CA, max €2m, single-stage, max one proposal.
• 4.1-4 Organisation of supporting actions and events related
to the presidency of the EU.
• Funding scheme: SA, max €100,000, single-stage, one or more
proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
57
Мероприятия
поддержки
• 4.2 – Responding to EU Policy needs
– 4.2-1 Investigator-driven clinical trials on
off-patent medicines for children.
– Funding scheme: collab. project, max €6m,
single-stage, one or more proposals.
– 4.2-2 Adverse drug reaction research.
– Funding scheme: collab. project, max €3m,
single-stage, one or more proposals.
– 4.23 New methodologies for clinical trials
in personalised medicine.
– Funding scheme: collab. project, max €3m,
single-stage, one or more proposals.
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
58
ГНУ «Институт биофизики и клеточной инженерии НАН
Беларуси»
Tel.: (+375 17) 284-17-49
Fax: (+375 17) 284-23-59
E-mail: [email protected]
WWW: http://www.ipb.org.by/
- войти в раздел « общая информация», а затем –
«НКТ»
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
59
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
60
Not legally binding: (based on draft documents) applicants must refer to final published work programme.
61